查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1133478

全球靜脈疾病治療市場-2022-2029

Global Venous Diseases Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

靜脈疾病治療市場的增長受到靜脈疾病患病率上升、對激光消融手術需求增加、靜脈疾病治療採用率上升、老年人口增加以及研究活動的推動。

靜脈疾病患病率上升預計將推動市場增長。

各種靜脈疾病的患病率上升，如血栓性深靜脈血栓形成和慢性靜脈功能不全，預計將在預測期內提振市場。 Bawakid 等人於 2021 年在麥加、吉達和達曼報告的一項研究提到，男性和女性慢性靜脈功能不全的總體患病率為 45.6%。 2021 年在沙特阿拉伯地區卡西姆地區的一家初級衛生保健中心進行的一項患病率研究還顯示，男性和女性的靜脈曲張患病率為 61.1%。一項新的基於問卷的研究結合多普勒超聲檢查報告顯示，韓國女性護士的靜脈曲張患病率較低，為 16.18%。這可以歸因於生活方式的快速變化和醫療保健的進步。對於靜脈曲張患者，最常見的 CEAP 等級為 C1，表明本研究中女性的輕度疾病表現為毛細血管擴張或網狀靜脈。年齡也是我們體內靜脈曲張發展和進展的主要風險因素。

年齡增長也是皮膚營養變化、血管內壓力增加和淺靜脈系統陽痿的重要因素。此外，在歐洲法國各地進行的一項大型研究報告稱，72.7% 的孕婦患有靜脈曲張。此外，較高的體重指數 (BMI) 與更晚期的靜脈曲張有關。此外，通過生活方式的快速變化以及特別是通過社交媒體輕鬆獲得醫療服務，人們對靜脈曲張及其風險因素的認識不斷提高，這推動了靜脈疾病治療市場的發展。

靜脈疾病治療費用高將阻礙市場增長

但是，靜脈疾病治療存在副作用，例如感染、疼痛和炎症、瘀傷、血栓和靜脈消融期間的腫脹。此外，腿部和腳部的疼痛和沈重感，尤其是在長時間站立或行走後，以及腿部的燒灼感和抽筋，都是阻礙市場增長的因素。

COVID-19 影響分析

COVID-19 的出現對全球靜脈疾病治療市場產生了重大影響。根據 2020 年 7 月發表在 Sage Journal 上的一篇文章，COVID-19 大流行已經影響到關鍵供應、勞動力和醫療護理，例如為冠狀病毒感染患者提供的急診和重症監護室 (ICU) 設施，導致資源偏差。在美國和許多其他國家，外科手術已被推遲或取消，手術室資源一直集中在應對大流行病上。有限的直接個人接觸和社交距離限制了獲得治療的機會。在大流行期間，患有靜脈、淋巴或血管異常的患者發現難以獲得專業護理。此外，越來越多的證據表明，患有動脈和靜脈血栓栓塞 (VTE) 和廣泛的凝血病的 COVID-19 在受影響的個體中更難以診斷。隨著情況從 COVID-19 中恢復，更多接受靜脈治療的患者可以輕鬆獲得適當的治療，從而推動市場發展。

全球靜脈疾病治療市場報告將提供對大約 50 多個市場數據表、50 多個數字和 200 頁（大約）的訪問。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按治療類型：市場細分
  • 按疾病類型：市場細分
  • 按產品類型：市場細分
  • 按最終用戶：市場細分
  • 按分銷渠道：市場細分
  • 按地區：市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 靜脈疾病發病率上升
      • 加大研發力度
    • 約束因素
    • 與治療藥物相關的副作用
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按治療類型

  • 手術
  • 硬化療法
  • 血管成形術或支架置入
  • 靜脈結紮和剝離
  • 卡瓦過濾器
  • 門診靜脈曲張切除術
  • 射頻消融治療
  • 激光治療
  • 其他治療

第 8 章按疾病類型

  • 深靜脈血栓性靜脈炎
  • 靜脈曲張和蜘蛛靜脈
  • 淺表性血栓性靜脈炎
  • 慢性靜脈功能不全
  • 靜脈潰瘍
  • 其他

第 9 章按產品類型

  • 消融裝置
  • 靜脈支架
  • 靜脈閉合
  • 硬化劑注射液
  • 其他

第 10 章，最終用戶

  • 醫院
  • 診所
  • 門診中心
  • 其他

第 11 章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 其他

第 12 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 13 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 按治療類型劃分的基準

第 14 章公司簡介

  • Biolitec AG Untere Viaduktgasse
    • 公司概況
    • 治療類型組合和描述
    • 主要亮點
    • 財務摘要
  • Teleflex Incorporated
  • BD
  • B. Braun Melsungen Ag
  • Alma Lasers
  • Becton Dickinson and Company
  • Koninklijke Philips N.V.

第 15 章全球靜脈疾病治療市場-DataM

簡介目錄
Product Code: DMPH5853

Market Overview

Venous Diseases Treatment Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of x% during the forecast period (2022-2029).

The venous disease includes blood clots in the legs, arms, brains, lungs, or internal organs (kidney, spleen, liver), deep vein thrombosis, chronic venous insufficiency, varicose and spider veins, and ulcers in the vein. The treatment for this disease includes drug therapy, endovenous laser ablation or radiofrequency ablation (RFA), sclerotherapy, and surgery.

Market Dynamics

The Venous Diseases Treatment market growth is driven by the rise in the prevalence venoous disease, rising demand for laser ablation procedures, rising adoption of venous diseases treatment, increase in the geriatric population, and research activities.

The increasing prevalence of venous diseases is expected to drive the market growth

The rising prevalence of different venous diseases such as blood clots deep vein thrombosis, and chronic venous insufficiency is expected to boost the market over the forecast period. In 2021, a study reported by Bawakid et al. in Makah, Jeddah and Dammam mentioned an overall prevalence of chronic venous insufficiency of 45.6% in both males and females. Also, a prevalence study conducted in 2021, in primary health care centers in Qassim region of Saudi Arabia region revealed that the prevalence of varicose veins among male and female was 61.1%. A new questionnaire-based study coupled with Doppler ultrasonography was showed in Republic of Korea reported less prevalence of varicose veins in female nurses 16.18%. This could be allocated to the rapid of changes in lifestyle and advancement in access to health care. Those people with varicose veins, the most commonly CEAP class was C1 which indicates a mild form of the disease presenting as telangiectasia or reticular veins among females in this study. In addition, age is a major contributing risk factor that rises the development and progression of varicose veins in our body.

Increasing in age is a significant factor in further skin trophic changes, growth in the endovascular pressure, and inability of the superficial venous system. Moreover, a large study done in different locations of France in Europe reported that 72.7% of pregnant women are suffering from varicose veins. Also, higher Body Mass Index (BMI) is associated to more advanced stages of varicose veins. Furthermore, fast changes in lifestyle and increased awareness about varicose veins and its risk factors through easier access to health care specifically through social media drives the venous disease treatment market.

The high cost of Venous Diseases Treatment will hamper the growth of the market

However, side effects associated with veous disease treatment such as infection during venous ablation, soreness and inflammation, bruising, blood clots and, swelling. In addition, pain and heaviness in the legs and feet, especially after long a time standing or walking for long periods of time and ,burning, and cramping in the legs restarestraintsmarket growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global venous diseases treatment market. As per the article published in Sage journals in July 2020, The COVID-19 pandemic has resulted in deviation of healthcare resources such as critical supplies, workforce, emergency and intensive care unit (ICU) facilities of patients infected with coronavirus. Interuuptions in surgical procedures in most countries such as United States had been postponed or cancelled and operating room resources were focused on management of the pandemic. Restrictions to direct personal contact and social distancing have controlled the access to care. Patients with venous and lymphatic disorders or vascular anomalies faced difficulty to get expert care in pandemic. In addition, there is increasing evidence that COVID-19 with both arterial and venous thromboembolic (VTE) disease and extensive coagulopathies is additionally difficult of the diagnosis of the affected patients. As the situation is recovering from COVID-19 more patients with venous treatment can easily access the proper treatment which drives the market.

Segment Analysis

The chronic venous insufficiency segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The chronic venous insufficiency segment is expected to boost the market over the period of the forecast. In 2022, the article published in Dermatol Therpeutics, chronic venous disorder (CVD) is most prevalent vascular disorder affecting up to 45% of the general population, with clinical relevation ranging from teleangiectasias to venous leg ulcers. The prevalence of CVD rises with age and it is more familiar in female than male. However, estimates of CVD prevalence vary widely from study to study 15-80% due to differences in study design and target population, and most of time CVD is underdiagnosed and undertreated, especially at lower severity levels. The pharmacological treatment can give proper symptomatic relief and it is considered as part of conservative treatment. Transcutaneous Lacer treatment is a safe and effective alternative option to sclerotherapy for treatment of C1 stage. Ultrasound-guided foam sclerotherapy (UGFS), high ligation and stripping, endovenous thermal ablation (EVTA) systems and non thermal non tumescent ablation systems are safe and effective first-line options for treatment of saphenous insufficiency.

Furthermore, in january 2022, The European Society for Vascular Surgery (ESVS) has published 2022 clinical practice guidelines on the management of chronic venous disease (CVD) of the lower limb to update its 2015 guidelines. The new guidelines foused on CVD of the lower limbs, related to pathology of the superficial, perforating and deep veins of the lower limb as well as to abdominal and pelvic venous pathology.

Geographical Analysis

North America region holds the largest market share of the global venous diseases treatment market

North America dominates the market for venous diseases treatment and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to technological advancement, presence of key players and easily availability of treatment. The article published in 2020 in J Vasc Surg Venous Lymphat Discord. Chronic venous insufficiency (CVI) resulting from venous reflux or obstruction leads to venous hypertension with edema, varicose veins, consequent pain, hyperpigmentation, and ulceration of the lower extremities. The CVI affects approximately 25 million adults in the United States region, with around 6 million suffering from advanced disease, and the annual cost of venous ulcer treatment and care is anticipated to be nearly $3 billion. Furthermore, for those people who are working for them CVI accounts for a loss of 2 million workdays per year, and almost 12% seek early retirement. Prolonged standing, Female sex, pregnancy, obesity; advanced lifestyle, venous reflux or obstruction, and deep venous thrombosis (DVT) are suspected risk factors for CVI. The increasing number of venous disease patient boosts the venous disease treatment market.

Competitive Landscape

The venous diseases treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Biolitec AG Untere Viaduktgasse, Teleflex Incorporated, B. Braun Melsungen Ag, Alma Lasers, Becton Dickinson and Company, and Koninklijke Philips N.V. among others. The major players are adopting several growth strategies such as treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the venous diseases treatment market globally.

For instance,

  • In February 2022, Becton, Dickison, and Company acquired Venclose Inc., a contributor of solutions for the treatment of chronic venous insufficiency (CVI) a disease that is the result of malfunctioning valves and can lead to varicose veins.

Becton, Dickison and Company

Overview:

The Becton, Dickinson and Company is an American multinational company that manufactures and distributes instrument systems, medical devices, and reagents for treatment of various diseases including venous disease.

Treatment Type Portfolio:

Venclose radiofrequency (RF) Ablation System: This system offers transformative solutions to improve outcomes in patients for chronic disease and able to the transition into novel care settings.

The global venous diseases treatment market report would provide access to approximately 50+ market data tables, 50+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Treatment Type
  • 3.2. Market Snippet By Disease Type
  • 3.3. Market Snippet By Product Type
  • 3.4. Market Snippet By End User
  • 3.5. Market snippet By Distribution channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising incidences of venous diseases
      • 4.1.1.2. The increasing number of research and development activities
    • 4.1.2. Restraints:
    • 4.1.3. Side effects related to therapeutics
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 7.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 7.2. Surgeries*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Sclerotherapy
  • 7.4. Angioplasty or Stenting
  • 7.5. Vein Ligation and stripping
  • 7.6. Vena Cava Filter
  • 7.7. Ambulatory Phlebectomy
  • 7.8. Radiofrequency Ablation Therapy
  • 7.9. Laser Treatment
  • 7.10. Others Therapies

8. By Disease Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 8.1.2. Market Attractiveness Index, By Disease Type
  • 8.2. Deep-vein Thrombophlebitis*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Varicose and Spider Veins
  • 8.4. Superficial Thrombophlebitis
  • 8.5. Chronic Venous Insufficiency
  • 8.6. Venous Ulcers
  • 8.7. Others

9. By Product Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.1.2. Market Attractiveness Index, By Product Type
  • 9.2. Ablation Devices*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Venous Stents
  • 9.4. Venous Closure Products
  • 9.5. Sclerotherapy Injection
  • 9.6. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinics
  • 10.4. Ambulatory Centers
  • 10.5. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. The U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Treatment type Benchmarking

14. Company Profiles

  • 14.1. Biolitec AG Untere Viaduktgasse*
    • 14.1.1. Company Overview
    • 14.1.2. Treatment type Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Teleflex Incorporated
  • 14.3. BD
  • 14.4. B. Braun Melsungen Ag
  • 14.5. Alma Lasers
  • 14.6. Becton Dickinson and Company
  • 14.7. Koninklijke Philips N.V.

LIST NOT EXHAUSTIVE

15. Global Venous Diseases Treatment market- DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us